Prelude Capital Management, LLC Atreca, Inc. Transaction History
Prelude Capital Management, LLC
- $1.85 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding BCEL
# of Institutions
9Shares Held
1.04MCall Options Held
0Put Options Held
0-
Bill & Melinda Gates Foundation Seattle, WA913KShares$00.09% of portfolio
-
Xtx Topco LTD London, X054.1KShares$00.0% of portfolio
-
Acadian Asset Management LLC Boston, MA44.1KShares$00.0% of portfolio
-
Gofen & Glossberg LLC20KShares$00.0% of portfolio
-
Endurance Wealth Management, Inc.10.6KShares$00.0% of portfolio
About Atreca, Inc.
- Ticker BCEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,876,000
- Description
- Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...